1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
69F990DA27215B05900258879006472BD
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/hybrid-work-models-medical-affairs-organizations-benefits-barriers-lessons-learned?opendocument
18
19opendocument
203.223.3.251
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Structure, Staffing and Budgets

Hybrid Work Models for Medical Affairs Organizations - Benefits/Barriers and Lessons Learned

ID: 5729


Features:

20 Info Graphics

6 Data Graphics

100+ Metrics

5 Narratives


Pages/Slides: 33


Published: 2022


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Hybrid Work Models for Medical Affairs Organizations - Benefits/Barriers and Lessons Learned"

STUDY OVERVIEW

With the pandemic waning, Medical Affairs leaders must decide what is the right hybrid model for each organization: continue to work remotely, return to all in-person, or develop a flexible hybrid approach?

This Best Practices, LLC study examines the changing forms, features, conditions, and triggers for hybrid work models that are best suited for a flexible and resilient Medical Affairs organization.

This study examines the benefits and barriers to remote vs. in-person work models and lessons learned from participants. This study probes and profiles how different medical organizations are adjusting remote vs. in-person work schedules, shrinking or expanding facilities, and planning post-pandemic.

Medical Affairs leaders can use to this report to develop a hybrid work model that is best suited for their organization.

KEY TOPICS

  • Key Decisions, Benefits and Barriers to Hybrid Model Success
  • Lessons Learned

KEY METRICS

I. Key Decisions, Benefits and Barriers to Hybrid Model Success

  • Effective facilities utilization tactics to accommodate hybrid and remote work during pandemic
  • Top lessons learned or best practices developed for using technology to enable effective remote work in a hybrid business model
  • Top three remote work benefits and barriers
  • Greatest benefits of remote / hybrid work environments for Medical Affairs organizations
  • Barriers / challenges to remote work for Medical Affairs organizations
  • Most notable lessons learned or best practices developed for effectively engaging and motivating employees who work in a remote work environment in hybrid business model
  • Future perspectives on hybrid work in Medical Affairs

II. Lessons Learned
  • Most notable lessons learned or best practices for making remote work environments and hybrid business model high functioning
  • Lessons for success
  • Lessons for successfully leading in a hybrid Medical Affairs world: Hybrid model opportunities
  • Lessons for successfully leading in a hybrid Medical Affairs world: Challenges
  • Lessons for successfully leading in a hybrid Medical Affairs world: Effective management practices
  • Lessons for successfully leading in a hybrid Medical Affairs world: Technology and digital enablement
  • Lessons for successfully leading in a hybrid Medical Affairs world: Staffing and talent considerations
  • Lessons for successfully leading in a hybrid Medical Affairs world: KPIs
  • Lessons for successfully leading in a hybrid Medical Affairs world: Field engagement

SAMPLE KEY FINDINGS

  • Top benefits: Commute time saved, greater employee autonomy, and ability to hire from a global talent pool
  • Top drawbacks: Missed social connections and potential for burnout

METHODOLOGY

The study engaged 51 Medical leaders from 39 pharma companies.

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Health Care; Communications; Clinical Research; Laboratories


Companies Profiled:
Alexion Pharmaceuticals; Asklepion Pharmaceuticals; LLC; ASC Therapeutics; AstraZeneca; Baxter BioScience; Bayer; Boehringer Ingelheim; Bionorica SE; Cipla; Eisai; Elevation Oncology; Lilly; Ferozsons Laboratories Limited; GE Healthcare; Grifols; Heron Therapeutics; Incyte; Ipsen; Jazz Pharmaceuticals; Kinnate Biopharma; MerckSerono; Merz Aesthetics; NexGen Healthcare; Novartis; Novavax; OPEN Health; Orchard Therapeutics; OTSUKA; Pfizer; Roche; Sage Therapeutics; Sandoz; Sanofi; Santen; Servier; Supernus; Terumo Corporation; Teva Pharmaceutical Industries Ltd; UCB Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.